Summit Therapeutics Share Discussion Threads

[chrisatrdg] 18/7/2016 18:34

AGM
I concur with AMM - in most points.With my previous point I was trying to say that they are looking for a deal as one alternative and have dealings with a number of people but they are not there yet.
I asked three questions:
1) Concerning funding comparisons NASDAQ versus AIMS comparing this year to last year - no real change plus comments per AMM.
2) Confidence in ability to secure approval in the US based on recent experiences by their DMD 'competitors' - clear they have learnt from those experiences and thought that Summits approach as being robust also add AMM comments.
3)Value of Summits C-diff drug on basis that it would replace current drugs used - it is a factor plus the reduced costs of less time spent in hospital.
I concur with AMM that the questions and answers provided robust answers and this year I was able to speak to all who were present from Summit.
We saw the whites of their eyes and I felt confident that we can be confident that Summit will eventually have two blockbuster drugs.

[hugus maximus] 18/7/2016 18:05

I can also vouch for that comment Freedosh.

If anyone cares to correct or question my observations please feel free but the following are deciphered from scribble I made:

Although it was mentioned that the appetite for Pharmaceuticals is not generally as good as it was a year or so ago, for those unaware of this: the american market has apparently more interest at an earlier stage in drug development than UK ... thus justifying a further reason for NASDAQ presence.

I noted Glyn also suggesting that the boards "confidence" in making it closer and closer to the January cliff edge, saw companies come and go ... some had even returned after initially expressing no interest, and it is usual to expect companies to miraculously appear with serious offers as the deal is about to close. Therefore I assume that a deal is certainly being discussed with various parties.

Aside from the suggestion that a placement would have been done a while ago if there had been no C Diff deal interest, I felt there was a palpable vibe that all was going according to plan. Not that hunches amount to anything, but as I was leaving Glyn simply said "it will be OK"!

I could certainly say today that I have a strong sense of trust for the board and after also chatting to Prof Stephen Davies, I felt there was an amazing passion from the scientific team that doesn't actually get aired on such occasions. He certainly seemed very buoyant about progress.

I also noted that in a comment Glyn made about "the DMD drug that will be first to market, won't necessarily be the best and although it will set a precedent as being the seen as the first great step, the follow ups will eventually be the real deal" He said ... "although the first drug to market won't change the poor DMD boys into Olympic rowers, it will be the first steps in seeing the composition of their muscle change enough to give their lives the potential for some sort of normality that isn't there for them now"

I mention the above paragraph as IMHO it is confirmation that Summit aren't sitting there wondering how successful SMTC1100 will be in P2 trials, but know there will be a long chain of improvements after P3 that will follow on. i.e. they are already far down the line with this and aren't lacking in confidence about initial first steps.

Again there was conversation about Beckers MD being on the cards for hopefully fixing with an eventual further pipeline follow up. (BMD has around the same number as sufferers as DMD)

Unlike the mess caused by Sarepta's DMD drug, Summit has certainly got a good grasp of what is needed for FDA approval .. indeed it was admitted that some of Sarepta's downfall may well have helped Summit with regard to some specific requirements that they got way wrong.

Those are some points I took away with me ... all good!
GLA HM

[luminoso] 18/7/2016 13:58

Well, hopefully they will do a C.diff deal first before paying themselves !

[someuwin] 18/7/2016 13:56

Dr Frank Armstrong, Non-Executive Chairman of Summit commented, "I am
pleased that shareholders have voted in favour of all binding votes
proposed at our AGM, although it is disappointing that the advisory vote
on this year's Remuneration Report did not receive sufficient support.

"Summit has a pay-for-performance philosophy on remuneration and
evaluates performance against the achievement of corporate objectives
for the year. The feedback received from shareholders is valued by the
Board as we implement our approved remuneration policy that aligns the
interests of all stakeholders and our overall objective of developing
potentially life transforming medicines to treat DMD and CDI."

[luminoso] 18/7/2016 13:55

Sounds good,freedosh, if so.

[freedosh] 18/7/2016 13:53

Yes very upbeat presentation by Glyn
If I understood correctly it will be a partnership or sale for Ridinazole or we would have already done a fund raising
Please correct me if I got that wrong Chris

[luminoso] 18/7/2016 13:53

Thanks Chris, look forward to more details later.

[joeblogg2] 18/7/2016 12:57

thks chris.!!

[luminoso] 16/7/2016 10:57

A double bottom formed on nasdaq, maybe. US investors are obsessive chartists, so could be good timing if the AGM gives some hope/hint/indication of a deal soon.

[hugus maximus] 15/7/2016 17:53

Depends how we ask the questions Chris!

[chrisatrdg] 15/7/2016 17:13

AGM starts at 10.30am next Monday so also do not expect a RNS at 12.00 that day either.
Not sure what we will learn Monday but sure a lot of questions not sure if there will be any answers but will soon find out.

[hugus maximus] 15/7/2016 13:39

No last minute C Diff deal announcement before the AGM?!

[chrisatrdg] 15/7/2016 10:59

Per gmcc this morning from the other board:

'DMD
Getting DMD drug FDA approvals problematic !

“The Santhera setback could point to further difficulties for Sarepta’s eteplirsen, argued RBC Capital analyst Simos Simeonidis in a July 14 note. “





“The Santhera setback could point to further difficulties for Sarepta’s eteplirsen, argued RBC Capital analyst Simos Simeonidis in a July 14 note.

“We believe today’s news makes a positive decision on eteplirsen even more unlikely. Here are the facts: FDA just notified a company with positive data from a randomized, placebo-controlled trial, with 5-6 times the number of more patients (n=64) than Sarepta’s trial that these data are not sufficient to even be reviewed for approval, and that they should come back in 3 years after they run another Phase III trial, primarily because they need to see confirmation of these data from a trial with a more appropriate endpoint,” he argued.”
------------------------------
For those attending the SUMM AGM the very best of luck with your endeavours in finding out actual current status :

C-Diff sale ?
Future funding /company cash reserves position ?
DMD SMTC1100 trial progress ( how many patients dosed ,how many recruited ?)'

[chrisatrdg] 15/7/2016 08:29

Per gmcc from the other board this morning:

'C-Diff antibiotics !

Unfortunately don’t have access to full report but good to see ridinilazole one of novel antibiotics mentioned !

“We anticipate that one or more of these medications will be approved within five years.” Hopefully ridinilazole will be done & dusted and curing patients long before then !!!!

•“Received: 3 May 2016
•Accepted: 8 Jul 2016
•Accepted author version posted online: 13 Jul 2016
Published online: 13 Jul 2016

"New antibiotics in clinical trials for Clostridium difficile"

Abstract INTRODUCTION:

There are limited number of approved therapies for C. difficile infections (CDI) and new treatments are needed to decrease recurrence rates. Over the past 5 years, four novel antibiotics have been evaluated in clinical trials that offer distinct advantages over existing therapies for the treatment of CDI.

AREAS COVERED:
This article reviews the preclinical and clinical studies of cadazolid, LFF571, ridinilazole, and surotomycin. The advantages that these antibiotics may have in the treatment of CDI infections is compared with current therapies metronidazole, vancomycin, and fidaxomicin. Expert commentary: The antibiotics examined have the potential to improve rates of CDI treatment without recurrence. We anticipate that one or more of these medications will be approved within five years.



Good luck everyone !

Note some info on other possible treatments

[sorrento06] 14/7/2016 22:27

What surprises me is that US holders haven't ditched their Nasdaq shares and bought into the UK listing with current FX rates.

[waterloo01] 14/7/2016 15:05

A biotech company developing a Duchenne muscular dystrophy drug has suffered a setback with the U.S. Food and Drug Administration. The company in trouble is Santhera Pharmaceuticals (SANN.SW), not Sarepta Therapeutics (SRPT) , so breathe.

Santhera's timetable to seek approval in the U.S. for its Duchenne drug Raxone is now pushed back to 2020 after the FDA said a second, successful phase III study will be required, the company said Thursday.

[waterloo01] 13/7/2016 08:15

The institutional investor owned 198,863 shares of the company’s stock after selling 3,357 shares during the period.

[sorrento06] 13/7/2016 07:09

Sold 1.6% of holdings...wow! What is more interesting is the 4 'Buy' ratings with average target of $19.

[football] 13/7/2016 00:06

Summit Therapeutics PLC (SMMT) Position Cut by Sphera Funds Management LTD.







Institutional Holders of SMMT

[chrisatrdg] 12/7/2016 13:36

I agree but is unlikely but roll on the AGM next Monday - you never know !!!

[deejay007] 12/7/2016 12:18

'Summ' news would be helpful

[theunluckyone] 11/7/2016 13:07

O/T On the contrary - The loathsome weather vane is now set to become PM.

[hugus maximus] 11/7/2016 13:05

Maybe the waters will become a little less stormy?!